. Author manuscript; available in PMC: 2015 Feb 26.

Published in final edited form as: Expert Rev Anticancer Ther. 2011 Sep;11(9):1379–1390. doi: 10.1586/era.11.132

Table 3.

Chemo immunotherapy for Previously Untreated CLL

Regimen	Trial	N	ORR (%)	CR (%)	PFS (months)
FCR	MDACC[90,91]	300	95	72	80
	GCLLSG CLL8[59]	408	95	44	52
FR	CALGB 9712[52,53]	51	90	47	42
PCR	Mayo-Ohio State[63]	64	91	41	34
BR	GCLLSG CLL2M[92]	119	90	33	NR

ORR = overall response rate; CR = complete response; PFS = progression-free survival; F = fludarabine; P = pentostatin; B = bendamustine; C = cyclophosphamide; R = rituximab; NR = not reported; N = number treated with regimen of interest